P. García Teijido

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.

F. Rivera, R. López, C. Grávalos, 2018, European journal of cancer.